US Patent Issued to Aclaris Therapeutics on July 29 for "Oral compositions of MK2 pathway inhibitor for treatment of immune conditions" (Missouri, Pennsylvania Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,195, issued on July 29, was assigned to Aclaris Therapeutics Inc. (Wayne, Pa.).

"Oral compositions of MK2 pathway inhibitor for treatment of immune conditions" was invented by Walter Smith (St. Louis), Joseph Monahan (Eureka, Mo.), Edward Hellriegel (Barto, Pa.), David Gordon (Ardmore, Pa.), Heidi Hope (St. Louis), John Robert Springer (Wentzville, Mo.) and Gary A. Decrescenzo (Parkville, Mo.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed."

The patent was filed on Nov. 8, 2023, under App...